Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $19.00, but opened at $18.30. Ascentage Pharma Group International shares last traded at $18.15, with a volume of 1,128 shares trading hands.

Wall Street Analyst Weigh In

AAPG has been the subject of several analyst reports. BTIG Research reissued a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. B. Riley Financial assumed coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft started coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Stock Down 0.7%

The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. The firm’s fifty day moving average price is $18.19 and its 200-day moving average price is $21.33.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several institutional investors have recently added to or reduced their stakes in AAPG. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth $383,000. Hsbc Holdings PLC acquired a new stake in Ascentage Pharma Group International in the 2nd quarter valued at about $391,000. Finally, UBS Group AG increased its holdings in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares in the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.